Detalhe da pesquisa
1.
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness".
Cell Rep Med;
5(6): 101595, 2024 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38838676
2.
Advances in targets in inflammatory breast cancer.
Int Rev Cell Mol Biol;
384: 125-152, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38637096
3.
Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines.
Biomedicines;
11(3)2023 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36979714
4.
An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.
Mol Cancer Ther;
21(9): 1449-1461, 2022 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35793453
5.
Erratum: Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis.
Mol Ther Oncolytics;
25: 305-306, 2022 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35663226
6.
Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.
Expert Opin Ther Targets;
26(5): 405-425, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35574694
7.
Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
JCO Precis Oncol;
6: e2000368, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35294223
8.
A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer.
Sci Rep;
12(1): 2478, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35169199
9.
ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells.
Biomedicines;
9(10)2021 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34680527
10.
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening.
Biomedicines;
9(7)2021 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34203351
11.
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance.
Nat Commun;
12(1): 3528, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34112795
12.
Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.
Bioorg Med Chem;
32: 116013, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33482584
13.
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.
Mol Cancer Ther;
20(2): 296-306, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33323457
14.
Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis.
Mol Ther Oncolytics;
18: 579-586, 2020 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32995482
15.
Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.
PLoS One;
15(4): e0231953, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32353087
16.
A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Br J Cancer;
120(12): 1105-1112, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31097774
17.
Corrigendum to "p85 beta-PIX is required for cell motility through phosphorylations of focal adhesion kinase and p38 MAP kinase"[Exp. Cell Res. 307(2) (2005) 315-328].
Exp Cell Res;
379(2): 245-247, 2019 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30992206
18.
Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Breast Cancer Res Treat;
176(1): 251, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982934
19.
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Breast Cancer Res Treat;
175(2): 339-351, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30826934
20.
MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer.
Biochem Biophys Res Commun;
489(4): 484-489, 2017 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28576487